Latest Conference Articles

March 1st 2020, 8:34pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Corey S. Cutler, MD, MPH, discusses how physicians can optimize treatment management in patients with both acute and chronic graft-versus-host-disease.

March 1st 2020, 7:51pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Jerald P. Radich, MD, discusses how the role of minimal residual disease (MRD) has evolved recently in clinical trials of hematologic malignancies.

March 1st 2020, 4:33am

HCC-TAG Conference

Yujin Hoshida, MD, PhD, discusses molecular subtyping in hepatocellular carcinoma.

March 1st 2020, 4:30am

HCC-TAG Conference

David J. Pinato, MD, PhD, discusses the lack of biomarkers in hepatocellular carcinoma.

February 29th 2020, 11:12pm

HCC-TAG Conference

Richard S. Finn, MD, reflects on data from the phase III REFLECT, RESORCE, CELESTIAL, and REACH-2 trials in hepatocellular carcinoma.

February 29th 2020, 10:58pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

At the 24th Annual International Congress on Hematologic Malignancies®, Sonali M. Smith, MD, detailed the critical clinical trial findings currently informing treatment selection in the frontline indolent non-Hodgkin lymphoma paradigm.

February 29th 2020, 10:45pm

HCC-TAG Conference

David J. Pinato, MD, PhD, highlights the clinical and biological challenges in identifying biomarkers in hepatocellular carcinoma, and the potential introduction of biomarkers in the future.

February 29th 2020, 10:39pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

A number of therapeutic options have become available in the frontline setting for patients with chronic lymphocytic leukemia, most recently the second-generation BTK inhibitor acalabrutinib.

February 29th 2020, 8:43pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Sonali M. Smith, MD, discusses the prognosis of patients with indolent non-Hodgkin lymphomas.

February 29th 2020, 7:55pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

With the main toxicities associated with CAR T-cell therapy being cytokine release syndrome and neurotoxicity, a multidisciplinary approach is vital to providing inclusive care to patients receiving this type of treatment.

February 29th 2020, 7:03am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Jorge E. Cortes, MD, shares his experience with tyrosine kinase inhibitors as treatment of patients with chronic myeloid leukemia.

February 29th 2020, 6:14am

HCC-TAG Conference

Neehar Parikh, MD, discusses the importance of multidisciplinary care in the treatment of patients with hepatocellular carcinoma.

February 29th 2020, 3:00am

HCC-TAG Conference

Ghassan K. Abou-Alfa, MD, discusses ways to optimize treatment selection for patients with hepatocellular carcinoma.

February 29th 2020, 2:21am

HCC-TAG Conference

Findings from the phase III IMbrave 150 trial represented the first time a treatment outperformed sorafenib for overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC), and the HCC world was understandably excited, said Ghassan K. Abou-Alfa, MD.

February 29th 2020, 12:27am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Newly approved and investigational agents are joining ruxolitinib for the treatment of myelofibrosis and may provide options for patients who progress or become intolerant to frontline JAK inhibitors.

February 28th 2020, 11:59pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Sagar Lonial, MD, FACP, discusses how the treatment landscape has evolved for patients with smoldering multiple myeloma.

February 28th 2020, 11:43pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Jae H. Park, MD, discusses the challenges in using CAR T-cell therapy in adult patients with acute lymphoblastic leukemia, and also highlights the potential role for off-the-shelf CAR T cells.

February 28th 2020, 9:42pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Despite advances made in the treatment of patients with diffuse large B-cell lymphoma, investigators are on a quest to move more novel agents through the pipeline, says Craig Moskowitz, MD, in a presentation during the 24th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma.

February 28th 2020, 11:06am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Prasad S. Adusumilli, MD, FACS, discusses the current role of chimeric antigen receptor T-cell therapy as treatment of patients with solid tumors and how this is evolving compared to CAR T cells in hematologic malignancies.

February 28th 2020, 8:55am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Joshua Brody, MD, discusses the development of in situ vaccinations, a vaccine that is created at the tumor site in patients with cancer.